Selected article for: "cell death and programmed cell death"
Title: Proceedings 31st Symposium ESVN-ECVN
  • Document date: 2019_12_21
    • ID: 4526ne4l_110
    Snippet: Human gliomas appear to exploit immune inhibitory mechanisms to maintain an immunosuppressive microenvironment and evade immune eradication. Binding of programmed cell death protein 1 (PD‐1) to its ligand (PD‐L1) promotes activated T‐cell exhaustion and apoptosis. Tumour cells (TCs) evade host's immune attack by expressing PD‐L1 and stimulating PD‐1 expression on tumour‐infiltrating lymphocytes (TILs). High‐grade and astrocytic glio.....
    Document: Human gliomas appear to exploit immune inhibitory mechanisms to maintain an immunosuppressive microenvironment and evade immune eradication. Binding of programmed cell death protein 1 (PD‐1) to its ligand (PD‐L1) promotes activated T‐cell exhaustion and apoptosis. Tumour cells (TCs) evade host's immune attack by expressing PD‐L1 and stimulating PD‐1 expression on tumour‐infiltrating lymphocytes (TILs). High‐grade and astrocytic gliomas express higher levels of PD‐L1 and immunotherapeutic targeting of the PD‐1‐PD‐L1 pathway is intensely studied; however, clinical evidence supporting these strategies’ efficacy is lacking.

    Search related documents:
    Co phrase search for related documents
    • apoptosis exhaustion and immune eradication: 1
    • cell death and clinical evidence: 1, 2
    • cell death and efficacy lack: 1
    • cell death and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • cell death and host immune attack: 1
    • cell death and human glioma: 1
    • cell death and immune attack: 1, 2, 3, 4, 5, 6
    • cell death and immune eradication: 1, 2
    • cell death and immunosuppressive microenvironment: 1, 2, 3, 4
    • cell death and strategy support: 1
    • cell death and TILs lymphocyte: 1
    • cell death and tumour cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • cell death protein and high level: 1, 2
    • cell death protein and immune attack: 1
    • cell death protein and immunosuppressive microenvironment: 1
    • cell death protein and tumour cell: 1
    • clinical evidence and efficacy lack: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • clinical evidence and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
    • clinical evidence and immune attack: 1